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The samples were subjected to mass spectrometric analysis after
pre-separation by UHLC Ultimate 3000 RS (Dionex, USA) in a col-
umn Dionex Acclaim RSLC 120 C18 (2.1  50 mm 120 A, 0.2 lm)
flow rate of 0.5 ml/min using as eluents 0.1% solution of formic
acid in water (A) and 0.1% solution of formic acid in atsetontrile
(B). Elution was carried out in gradient mode: (%B): 0–3min (5%),
3–28min (5–95%), 28–30 min (95%), 30–31 min (95–5%), 31–35 min
(5%). Mass spectrometry was carried out on ESI-qTOF ultrahigh
resolution Maxis 4G (Bruker, Germany) in the positive ion detec-
tion mode range 50–1000 m/z, 2 Hz with the following settings
electrospray ion source: CV 3800 V, Nebulizer gas 1 bar, Dry Gas
8 l/min, Dry Temp: 200 C.
Results: It was found that the DNA which was cleaved with
acid hydrolysis in the result contained single DNA bases. The
samples were stable at 4 C for at least 7 days. The optimal eluent
for solid phase extraction of DNA is 80% solution of methanol in
water. The number of DNA adducts was evaluated by the inte-
grated value of the mass spectrometric response detector. It
was shown that most amount of adducts 4-hydroxy-1-(3-
pyridyl)-1- butanone and N3-(2-carbamoyl-2-hydroxyethyl)ade
nine was found in DNA samples derived from tumor tissue. The
adduct N7-(2-carbamoyl-2-hydroxyethyl)guanine was found in
tumor tissue samples and DNA derived from plasma, as well as
in all samples of healthy tissue.
Conclusion: The established protocol of DNA sample prepara-
tion followed by analysis using a mass spectrometer high resolu-
tion allows to detect the content of the DNA adducts in small DNA
probes (100 ng). We found, that acid hydrolysis is cheaper and
more practical in comparison to enzymatic digestion in order to
generated samples containing single DNA bases without damag-
ing the structure of adducts.
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Mutations in BRCA1 and CHEK2 genes associated with
hereditary breast cancer were tested in 7920 randomly selected
individuals of Novosibirsk (Russia). Mutations BRCA1 5382insC
and CHEK2 1100delC were the most frequent, they were found
in 0.25% and 0.4% of the general population respectively. We
suggested to find mutations carriers by the screening of all
breast/ovary cancer patients for the most frequent mutations
(BRCA1 5382insC and CHEK2 1100delC) with subsequent analysis
of the first-line relatives of cancer patients if one of the mutations
was found.
From June 2013 till January 2015, all patients from Novosibirsk
regional oncology hospital with the diagnosis of breast cancer
and some patients with the diagnosis of ovary cancer were tested
for mutations BRCA1 5382insC and CHEK2 1100delC. A total of
2655 cancer patients were analyzed independently of their family
history. We found 122 mutations carriers, among them 99
patients with mutations in BRCA1 gene and 23 patients with
mutation CHEK2 1100delC. Among mutation carriers, 105 patients
agreed to have a medical genetic counseling and after pedigree
analysis 193 first-line relatives aged above 25 years were eluci-
dated. One hundred ten first-line relatives of mutation carriers
were analyzed for the mutations presence and 40 mutations car-
riers were found among relatives.
From September 2013 till December 2013, 32 relatives of BRCA
mutation carriers underwent breast MRI. In 5 cases, breast can-
cer was detected by MRI and all cancers except one were con-
firmed histologically with biopsy analysis. Importantly, all
tumors were 5 mm and less in size, stage I cancer was detected
in all cases.
At a follow-up of 1.5 years, all 105 mutation carrier probands
were interviewed by phone regarding possible relapse and/or
possible primary cancer in their relatives. Five of 105 probands
lost to follow-up may have died. Among responding 100 patients,
2 died as reported by relatives, relapse was reported in 7 probands
– mutation carrier probands, primary tumors were reported in 8
relatives of probands.
Mutation carrier probands reported one bilateral breast
cancer, four ovary cancers, one bladder cancer and one non-
specified oncogynecological tumor.
There were five cases of primary breast cancer, one ovary can-
cer, one colon cancer, one lung cancer among relatives of breast
cancer patients with mutations. The frequency of tumors found
in mutation carriers exceeded the average frequencies of cancer
for this population.
The economic value of the regional genetic screening can be
easily estimated according to the data obtained in this study
and data on treatment cost for stage I and stage IV breast cancer.
To summarize briefly, the screening of hot-spot mutations
provides not only increase of lifespan expectancy and life quality
for mutation carriers, but can be also a tool for financial saving of
medical system due to the increase of early stage breast cancer
detection.
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The hypothesis of the possible evolutionary role of tumors
suggests that hereditary tumors may supply evolving multicellu-
lar organisms with extra cell masses for the expression of newly
evolving genes (Kozlov, 2014). After expression of novel genes in
tumor cells, tumors may differentiate in new directions and give
rise to new cell types, tissues and organs.
In the presentation, the bulk of data supporting the positive
evolutionary role of tumors will be reviewed, obtained both in
the lab of the author and from the literature sources.
The following issues will be addressed: the widespread occur-
rence of tumors in multicellular organisms; features of tumors
that could be used in evolution; the relationship of tumors to
evo-devo; examples of recapitulation of some tumor features in
recently evolved organs; the types of tumors that might play the
role in evolution; examples of tumors that already have played
the role in evolution.
The discussion of experimental confirmation of nontrivial pre-
dictions of the hypothesis will include the analysis of evolution-
ary novelty of tumor-specifically expressed EST sequences;
ELFNI – AS1, a human gene with possible microRNA function
expressed predominantly in tumors and originated in primates;
PBOV1, a human gene of the recent de novo origin with predicted
highly tumor-specific expression profile; and the evolutionary
novelty of human cancer/testis antigen genes; the data obtained
on transgenic fish tumors regression model; and other data.
It can be concluded that expression of protogenes, evolution-
arily young and/or novel genes in tumors might be a new
biological phenomenon, a phenomenon of carcino-evo-devo
genes, predicted by the hypothesis of evolution by tumor
neofunctionalization.
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Integrated genomic analyses of breast cancer, relevance for better
prognosis and treatment evaluation
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Combined analyses of molecular data, such as DNA copy-
number alteration, mRNA and protein expression, point to biolog-
ical functions and molecular pathways being deregulated in mul-
tiple cancers. Genomic, metabolomic and clinical data from a
variety of solid cancers and model systems are emerging and
can be used to identify novel patient subgroups for tailored ther-
apy and monitoring. The first solid tumor to be profiled by expres-
sion arrays was carcinoma of the breast. The most reproducible
classification by mRNA expression is based on the biological enti-
ties referred to as the intrinsic subtypes; Luminal A, Luminal B,
Basal-like, HER2 enriched, and the Normal-like groups. In the past
decade a number of molecular studies to classify breast cancer
have added one or two additional molecular levels, most fre-
quently DNA copy number, and gene sequencing. However, few
of the studies have integrated more than two levels of informa-
tion from the same patients. We have in our lab collected several
layers of high throughput molecular data, TP53 mutation status
and high throughput paired end sequencing on a dataset of 110
patients. This dataset was clustered according to each molecular
level studied using an unbiased, unsupervised clustering, and
survival KM plots for each patient subgroup was created. While
some samples always cluster together at any molecular level,
others cluster in different groups according to each particular
molecular endpoint. Therefore, we used an integrated approach
to understand breast cancer heterogeneity by modeling mRNA,
copy number alterations, microRNAs, and methylation in a path-
way context utilizing the pathway recognition algorithm using
data integration on genomic models (PARADIGM). We show that
massive interleukin signaling profiles are observed in invasive
cancers and are absent or weakly expressed in healthy tissue
but already prominent in ductal carcinoma in situ, together with
ECM and cell-cell adhesion regulating pathways. A good correla-
tion was observed between methylation and mRNA expression
based classification (p = 2.29  106). Using PARADIGM based on
mRNA and miRNA expression, CNAs, and methylation five new
clusters with survival differences were revealed. Given the
increasing importance of immune constitution for the success
of chemotherapy and targeted treatment, this additional infor-
mation may prove useful in the clinic in the future.
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Background: The aim of this work was to assess the potential
of the optical methods for studying erythrocytes (Er) and blood
serum (BS) of patients with colorectal cancer (CC).
Methods: A total of 26 persons (52 + 8 years old) with CC (histo-
logically – adenocarcinoma) in the T1–2 stage (the 1st group con-
sisting of 10 patients) and in the terminal stage T3–4 (the 2nd
group involving 16 patients) were examined. The metastases (in
the liver area) were detected in 6 patients; the remaining patients
had no metastases. The degree of lymph node involvement in
most patients was not determined, the ten corresponding N1.
The control group consisted of 16 healthy people (50 + 6 years
old). Electric and viscoelastic Er parameters were investigated
by dielectrophoresis, their membrane structure – by TLC and
gas chromatography. The optical properties of BS were studied
by the methods of ellipsometry. The reaction of the monoclonal
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